Registration Now Open for March 9 Patient Forum!
MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, will bring together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provide networking opportunities across the melanoma community.
Challenge Accepted: MRA 2020 - 2021 Annual Report
This was a year like no other. COVID-19 presented new challenges that required new ways of thinking. At MRA, confronting challenges is part of our DNA. We never stop challenging ourselves, no matter the odds or obstacles, in pursuit of conquering melanoma and saving lives.
Advancing Melanoma Research in Times of Uncertainty
Each year, the annual MRA Scientific Retreat brings hundreds of people from across the melanoma research ecosystem together to exchange ideas, report on scientific progress, celebrate achievements, and mourn the losses. In these ways, the 2021 Retreat was no different.
Fueling a Revolution: Driving Research Forward
MRA is powering a revolution in melanoma research. A revolution that is not only benefiting patients with melanoma but also impacting the field of oncology at large.
Maintaining Momentum in Melanoma Research
The last decade has been one of substantial progress and hope for many melanoma patients, researchers, and clinicians. With 12 new therapeutic approaches now approved to treat melanoma, many advanced-stage patients are seeing their tumors shrink or disappear, and are experiencing renewed hope for a brighter future.
Coronavirus: What People with Cancer Should Know
Coronaviruses are a large family of viruses that are common in people and many different species of animals. CDC is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China and has now been detected in the United States and many other countries.
Melanoma Research Advances – 2019 in Review
During 2019, melanoma research continued its rapid pace of advancement, with FDA approval of a new adjuvant therapy treatment option, several first-in-human clinical trials, and significant progress towards earlier intervention.
Safe and Sound: Balancing Safety with Innovation in American Sunscreens
Currently, Americans have access to 16 sunscreen active ingredients approved by the Food and Drug Administration (FDA) to prevent skin cancer. The last time a new OTC (Over the Counter) sunscreen ingredient was added to the FDA sunscreen monograph was 1999. Meanwhile, Europeans have access to 29 sunscreen active ingredients. In the United States there are currently eight new sunscreen ingredients that are pending FDA review, which have been used in Europe – many for over ten years. These new, and potentially better, active ingredients could allow sunscreens to last longer and provide better full spectrum coverage that could help us reverse trends of increasing melanoma incidence in this country. Unlike in Europe where sunscreens are classified as cosmetics, in the United States the FDA is required to evaluate all active ingredients in sunscreens as OTC drugs. Meaning, that all U.S. sunscreen ingredients must be found generally recognized as safe and effective (GRASE) in the same manner as other OTC medications. The FDA says that this is critical to keeping us safe, but is it possible to balance innovation and safety?
Sunscreen Laws may Hinder Protecting Children from Exposure
With the launch of summer comes conventional discussion around ranking sunscreens, and chatter between the experts to parse what should be considered in choosing the most effective among them. It’s also a key conversation among parents heading into the season with an eye on protecting their children from sun exposure. Yet, something remaining a central concern among those parents is the public policy surrounding use of sunscreen in schools.